The metabolism of primaquine to its active metabolite is dependent on CYP 2D6

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Pybus, Brandon S ^a   Marcsisin, Sean R ^a   Jin, Xiannu ^a   Deye, Gregory ^a   Sousa, Jason C ^a   Li, Qigui ^a   Caridha, Diana ^a   Zeng, Qiang ^a   Reichard, Gregory A ^a   Ockenhouse, Christian ^a   Bennett, Jason ^a   Walker, Larry A ^b   Ohrt, Colin ^a   Melendez, Victor ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; PAROXETINE; PHENOL DERIVATIVE; PRIMAQUINE; ANTIMALARIAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG METABOLISM; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; SPOROZOITE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GENETICS; HYDROXYLATION; MALARIA; METABOLISM; PARASITOLOGY;

ANIMALS; ANTIMALARIALS; CYTOCHROME P-450 CYP2D6; HYDROXYLATION; MALARIA; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PLASMODIUM BERGHEI; PRIMAQUINE;

EID: 84879082233     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-212     Document Type: Article

References (23)

1. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, Song J, Yeung S, Dondorp AM, Day NP, White NJ, White LJ, PLoS One 2012 7 37166 10.1371/journal.pone.0037166 22662135
2. Primaquine revisited six decades after its discovery. Vale N, Moreira R, Gomes P, Eur J Med Chem 2009 44 937 953 10.1016/j.ejmech.2008.08.011 18930565
3. 8-Aminoquinolines: future role as antiprotozoal drugs. Tekwani BL, Walker LA, Curr Opin Infect Dis 2006 19 623 631 10.1097/QCO.0b013e328010b848 17075340 (Pubitemid 44665470)
4. Metabolism of primaquine by liver homogenate fractions: evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. Constantino L, Paixao P, Moreira R, Portela MJ, Do Rosario VE, Iley J, Exp Toxic Pathol 1999 51 299 303 10.1016/S0940- 2993(99)80010-4 (Pubitemid 29334356)
5. Cytochrome P450-dependent toxic effects of primaquine on human erythrocytes. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA, Tox App Pharm 2009 241 14 22 10.1016/j.taap.2009.07.012
6. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, Vuong C, Sciotti RJ, Reichard GA, Kozar MP, Walker LA, Ohrt C, Melendez V, Malar J 2012 11 259 10.1186/1475-2875-11-259 22856549
7. Hydroxylated metabolites of the antimalarial drug primaquine. Vasquez-Vivar J, Augusto O, J Biol Chem 1992 267 6848 6854 1313024
8. Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes. Idowu OR, Peggins JO, Brewer TG, Kelley C, Drug Metab Dispos 1995 23 1 17 7720510
9. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. De Gregori M, Allegri M, De Gregori S, Garbin G, Tinelli C, Regazzi M, Govoni S, Ranzani GN, Current Drug Metabolism 2010 11 276 282 10.2174/138920010791196274 21171195
10. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Bradford LD, Pharmacogenomics 2002 3 229 243 10.1517/14622416.3.2.229 11972444 (Pubitemid 34223859)
11. Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Scheer N, Kapelyukh Y, McEwan J, Beuger V, Stanley LA, Rode A, Wolf CR, Mol Pharmacol 2012 81 63 72 10.1124/mol.111.075192 21989258
12. Guidelines for the treatment of malaria. WHO, Organization WH, 2 2010 http://whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf
13. Rationale for short course primaquine in Africa to interrupt malaria transmission. Eziefula AC, Gosling R, Hwang J, Hsiang MS, Bousema T, Von Seidlein L, Drakeley C, Primaquine in Africa Discussion G, Malar J 2012 11 360 10.1186/1475-2875-11-360 23130957
14. Primaquine for reducing Plasmodium falciparum transmission. Graves PM, Gelband H, Garner P, Cochrane Database Syst Rev 2012 9 D008152 22972117
15. Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations. Myint HY, Berman J, Walker L, Pybus B, Melendez V, Baird JK, Ohrt C, Am J Trop Med Hyg 2011 85 1010 1014 10.4269/ajtmh.2011.11-0498 22144436
16. Primaquine-induced hemolytic anemia: formation of free radicals in rat erythrocytes exposed to 6-methoxy-8-hydroxylaminoquinoline. Bolchoz LJ, Gelasco AK, Jollow DJ, McMillan DC, J Pharmacol Exp Ther 2002 303 1121 1129 10.1124/jpet.102.041459 12438535 (Pubitemid 35424397)
17. Primaquine-induced hemolytic anemia: effect of 6-methoxy-8- hydroxylaminoquinoline on rat erythrocyte sulfhydryl status, membrane lipids, cytoskeletal proteins, and morphology. Bolchoz LJ, Morrow JD, Jollow DJ, McMillan DC, J Pharmacol Exp Ther 2002 303 141 148 10.1124/jpet.102.036921 12235244
18. Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. Bolchoz LJ, Budinsky RA, McMillan DC, Jollow DJ, J Pharmacol Exp Ther 2001 297 509 515 11303037 (Pubitemid 32377979)
19. Primaquine induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine. Bowman ZS, Oatis JE Jr, Whelan JL, Jollow DJ, McMillan DC, J Pharmacol Exp Ther 2004 309 79 85 10.1124/jpet.103.062984 14724225 (Pubitemid 38393117)
20. Primaquine-induced hemolytic anemia: role of splenic macrophages in the fate of 5-hydroxyprimaquine treated rat erythrocytes. Bowman ZS, Jollow DJ, McMillan DC, J Pharm Exp Ther 2005 315 980 986 10.1124/jpet.105.090407 (Pubitemid 41635383)
21. Structure-activity relationships of putative primaquine metabolites causing methemoglobin formation in canine hemolysates. Link CM, Theoharides AD, Anders JC, Chung H, Canfield CJ, Toxicol Appl Pharmacol 1985 81 192 202 10.1016/0041-008X(85)90155-3 4060148 (Pubitemid 16204105)
22. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Yu AM, Idle JR, Gonzalez FJ, Drug Metab Rev 2004 36 243 277 10.1081/DMR-120034000 15237854 (Pubitemid 38802489)
23. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Zanger UM, Raimundo S, Eichelbaum M, Naunyn Schmiedebergs Arch Pharmacol 2004 369 23 37 10.1007/s00210-003-0832-2 14618296 (Pubitemid 38161221)